FDA has approved Cyramza (ramucirumab) treatment of advanced or metastatic gastric cancer or gastro-
The FDA has approved Cyramza (ramucirumab) 10mg/mL injection for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
alexandra phan md says :"Ramucirumab is a fully humanized monoclonal antibody against the vascular endothelial growth factor receptor 2 (VEGFR2). This is a biological agent that has been tested in several cancers including stomach and lung cancers. On Monday, the FDA approved this agent for the treatment of patients with advanced gastric or gastro-esophageal junction (GEJ) cancers. ......"
danièle
Comments
-
Thank you dfd24
Hi Danièle,
Thanks for sharing these important updates!
Take care
0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 121.2K Cancer specific
- 2.8K Anal Cancer
- 440 Bladder Cancer
- 306 Bone Cancers
- 1.6K Brain Cancer
- 28.4K Breast Cancer
- 391 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 12.9K Head and Neck Cancer
- 6.3K Kidney Cancer
- 666 Leukemia
- 789 Liver Cancer
- 4.1K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 235 Multiple Myeloma
- 7.1K Ovarian Cancer
- 53 Pancreatic Cancer
- 486 Peritoneal Cancer
- 5.3K Prostate Cancer
- 1.2K Rare and Other Cancers
- 532 Sarcoma
- 717 Skin Cancer
- 647 Stomach Cancer
- 190 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards